NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
Clinical Trials
8 trialsNCT01824901 2023-06-29
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 1/2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT01791985 2022-08-22
RADICAL
Imperial College London
Phase 1/2 Completed
NCT04439240 2021-06-29
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02965378 2021-05-27
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Phase 2/3 Completed
NCT01213160 2016-06-29
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
AstraZeneca
Phase 1 Completed
NCT01202591 2016-02-11
GLOW
AstraZeneca
Phase 1/2 Completed